MOLE', Daniela
 Distribuzione geografica
Continente #
NA - Nord America 2.070
EU - Europa 605
AS - Asia 401
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 3
OC - Oceania 1
Totale 3.083
Nazione #
US - Stati Uniti d'America 2.067
CN - Cina 228
UA - Ucraina 154
PL - Polonia 136
DE - Germania 101
TR - Turchia 86
SG - Singapore 79
IT - Italia 66
GB - Regno Unito 59
SE - Svezia 43
FI - Finlandia 35
RU - Federazione Russa 6
BE - Belgio 4
ID - Indonesia 4
CA - Canada 3
EU - Europa 3
VN - Vietnam 3
BR - Brasile 1
CL - Cile 1
EC - Ecuador 1
FR - Francia 1
IR - Iran 1
NZ - Nuova Zelanda 1
Totale 3.083
Città #
Woodbridge 268
Chandler 205
Fairfield 199
Ashburn 193
Jacksonville 185
Houston 162
Warsaw 136
Ann Arbor 132
Wilmington 85
Seattle 75
Cambridge 65
Singapore 58
Addison 52
Nanjing 44
Beijing 42
Izmir 42
Princeton 35
Boardman 32
Shanghai 26
Dearborn 25
Ferrara 25
Bremen 20
Milan 19
San Diego 17
Shenyang 17
Jinan 15
Mountain View 13
Los Angeles 12
Nanchang 12
Santa Clara 11
New York 10
Washington 10
Tianjin 9
Hebei 8
Jiaxing 8
Auburn Hills 7
Changsha 7
Orange 6
Indiana 5
Norwalk 5
Brussels 4
Cagliari 4
Jakarta 4
Ningbo 4
Redwood City 4
Tappahannock 4
Augusta 3
Chengdu 3
Dong Ket 3
Falls Church 3
Guangzhou 3
Hefei 3
Kunming 3
Lanzhou 3
Leawood 3
Padova 3
Taizhou 3
Bologna 2
Helsinki 2
Kingston 2
London 2
Rome 2
Taiyuan 2
Ardabil 1
Canaro 1
Changchun 1
Des Moines 1
Dongguan 1
Fuzhou 1
Haikou 1
Hangzhou 1
Harbin 1
Kilburn 1
Knoxville 1
Munich 1
Navegantes 1
Nürnberg 1
San Francisco 1
San Mateo 1
Southwark 1
Toronto 1
Tosagua 1
Walnut 1
Totale 2.386
Nome #
PKC COME NUOVO TARGET MOLECOLARE NEL CONTROLLO DELLA PROLIFERAZIONE CELLULARE DEI TUMORI NEUROENDOCRINI 166
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 159
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 132
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 126
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 126
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 118
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 117
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 117
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 116
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 115
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 112
Growth hormone excess promotes breast cancer chemoresistance 108
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 108
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 106
PKCδ plays an important in regulating human medullary thyroid carcinoma cell viability 93
Protein Kinase C: A Putative New Target for the Control of Human Medullary Thyroid Carcinoma Cell Proliferation in Vitro 83
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 77
Differential mTOR and PI3K Pathway Activation in Human Bronchial Carcinoids 77
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 76
Everolimus reduces human ACTH secreting pituitary adenoma in vitro cell viability by inhibiting IGF-I down-stream signalling 75
A Novel PKC beta II Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells 74
GH influences breast cancer chemoresistanec independently of cell cycle perturbations 74
ctivation of EGFR promotes ACC cell proliferation by inducing VEGF autocrine secretion 71
Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels 70
Mitotane reduces the chemoresistance phenotype in an adrenocortical carcinoma cell line 69
Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability 69
mTOR inhibitors hamper cell viability in selected human medullary thyroid carcinoma primary cultures 67
Targeting PKC in human pancreatic neuroendocrine tumor cells 66
GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells 65
Evaluation of PKC isoforms expression in thyroid cells lines and effects of a PKC beta II selective inhibitor 61
PRKCD Is a Target of miR-26a in ACTH Pituitary Adenoma 55
miR-26a regulates cell cycle in ACTH-secreting pituitary adenomas through Protein Kinase C delta 55
mTOR inhibition influences cell viability of medullary thyroid carcinoma primary cultures 50
null 40
miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C  20
Totale 3.113
Categoria #
all - tutte 12.800
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.800


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020506 0 0 0 95 39 86 53 64 47 82 28 12
2020/2021416 39 33 16 74 9 50 10 53 5 51 60 16
2021/2022313 13 28 15 3 13 18 10 8 8 34 43 120
2022/2023422 39 39 20 55 77 52 19 36 57 0 15 13
2023/2024252 21 22 11 9 16 41 9 77 3 3 2 38
2024/202599 22 19 58 0 0 0 0 0 0 0 0 0
Totale 3.113